agosto 02 2024

Mayer Brown advises SERB Pharmaceuticals and its majority shareholder Charterhouse Capital Partners on the structuring of the acquisition of RSDL® (Reactive Skin Decontamination Lotion)

Share

Mayer Brown advises SERB Pharmaceuticals and its majority shareholder Charterhouse Capital Partners on the structuring of the acquisition of RSDL® (Reactive Skin Decontamination Lotion) from Emergent BioSolutions Inc. (NYSE: EBS). RSDL® is a medical device produced as a kit that removes or neutralizes chemical warfare agents from the skin.

Contacto

Servicios e Industrias Relacionadas

Stay Up To Date With Our Insights

See how we use a multidisciplinary, integrated approach to meet our clients' needs.
Subscribe